Intended for healthcare professionals


Isotretinoin: Regulator adds prescribing safeguards after review of side effects

BMJ 2023; 383 doi: (Published 02 November 2023) Cite this as: BMJ 2023;383:p2545
  1. Elisabeth Mahase
  1. The BMJ

Two prescribers, including a dermatology specialist, must now sign off new prescriptions of the acne medicine isotretinoin (brand names include Roaccutane and Reticutan) for patients aged under 18,1 after concerns were raised over potential sexual and mental health side effects, including suicide.2

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) carried out a safety review of all the available evidence, including information provided by …

View Full Text

Log in

Log in through your institution


* For online subscription